Skip to main content

Table 3 Rates of responses in different sexes, ages, genotypes, treatment types and viral titres (N = 136)

From: Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients

Factor Total Treated RVR (%) EVR (%) BTR (%) ETR (%) NR (%) SVR (%)
SEX        
Male
Female
69
67
3(4.3)
2(2.9)
7(10.1)
6(8.9)
4(5.8)
6(8.9)
52(75.4)
48(71.6)
17(24.6)
19(28.3)
48(69.6)
33(49.3)
AGE-years        
<20 6 0 0 0 5(83.3) 1(16.7) 4(66.7)
21-30 42 1(2.4) 4(9.5) 2(4.8) 35(83.3) 7(16.7) 32(76.2)
31-40 43 2(4.7) 6(13.9) 5(11.6) 28(65.1) 15(34.9) 21(48.8)
41-50 36 2(5.6) 2(5.6) 2(5.6) 27(75) 9(25) 19(52.8)
51-60 & above 9 0 1(11.1) 1(11.1) 5(55.6) 4(44.4) 4(44.4)
GENOTYPE        
None-1 124 5(4) 12(9.7) 9(7.3) 92(74.2) 32(25.8) 74(59.7)
1 & Mixed 12 0 1(8.3) 1(8.3) 8(66.7) 4(33.3) 7(58.3)
TREATMENT        
INF+RBV 86 4(4.7) 8(9.3) 10(11.6) 60(69.8) 26(30.2) 46(53.5)
PEGINF+RBV 50 1(2) 5(10) 0 40(80) 10(20) 35(70)
PRE-TREATMEN        
VIRAL LOAD        
<200 IU/mL 112 4(3.6) 13(11.6) 9(8) 81(72.3) 31(27.7) 65(58)
>200 IU/mL 24 1(4.2) 0 1(4.2) 19(79.1) 5(20) 16(66.7)
TOTAL 136 5(3.6) 13(9.6) 10(7.4) 100(73.5) 36(26.5) 81(59.6)
  1. RVR: Rapid virological response; EVR: Early Virological response; BTR: Breakthrough response; ETR: End of treatment response; NR: Non-responders; SVR: Sustained virological response; INF: Interferon; PEG-INF: Pegylated interferon; RBV: ribavirin; IU/International units